Northern Trust Corp Vista Gen Therapeutics, Inc. Transaction History

Northern Trust Corp

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.12 - $0.3 $11,299 - $28,248	94,163 Added 5.39%	1,841,318 $220,000
Q4 2022 Feb 13, 2023	BUY	$0.09 - $0.16 $22,196 - $39,459	246,623 Added 16.44%	1,747,155 $174,000
Q3 2022 Nov 14, 2022	SELL	$0.14 - $1.07 $12,392 - $94,712	-88,516 Reduced 5.57%	1,500,532 $228,000
Q2 2022 Aug 12, 2022	SELL	$0.88 - $1.73 $40,440 - $79,502	-45,955 Reduced 2.81%	1,589,048 $1.4 Million
Q1 2022 May 13, 2022	SELL	$1.14 - $2.09 $363,982 - $667,301	-319,283 Reduced 16.34%	1,635,003 $2.03 Million

Q4 2021 Feb 08, 2022	SELL	$1.67 - $2.76 $72,053 - $119,082	-43,146 Reduced 2.16%	1,954,286 $3.81 Million
Q3 2021 Nov 15, 2021	SELL	$2.62 - $3.45 $214,177 - $282,027	-81,747 Reduced 3.93%	1,997,432 $5.47 Million
Q2 2021 Aug 13, 2021	BUY	$1.96 - $3.15 $3.56 Million - $5.72 Million	1,816,239 Added 690.74%	2,079,179 $6.55 Million
Q1 2021 May 12, 2021	BUY	$1.89 - $2.96 $314,628 - $492,751	166,470 Added 172.56%	262,940 $560,000
Q4 2020 Feb 11, 2021	SELL	$0.65 - $1.94 $6,055 - $18,073	-9,316 Reduced 8.81%	96,470 $187,000
Q3 2020 Nov 16, 2020	BUY	$0.48 - $1.03 $12,529 - $26,887	26,104 Added 32.76%	105,786 $74,000
Q1 2020 May 14, 2020	BUY	$0.32 - $0.8 $3,212 - $8,032	10,040 Added 14.42%	79,682 $35,000
Q4 2018 Feb 12, 2019	BUY	$1.28 - $2.24 $55,953 - $97,919	43,714 Added 168.6%	69,642 $104,000
Q1 2018 May 09, 2018	BUY	$0.91 - $1.73 $13,659 - $25,967	15,010 Added 137.48%	25,928 $24,000
Q3 2017 Nov 13, 2017	BUY	$1.54 - $1.85 $16,813 - $20,198	10,918	10,918 $17,000

2.7M

Ticker VTGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 206,836,000
Market Cap $720M
Description
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III d...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.